Some companies chase trends, others stalk the real monster in the room. Sparrow Pharmaceuticals just locked in a $95 million Series B, and their prey is cortisol, the biochemical saboteur that laughs at insulin, spikes blood sugar, and keeps type 2 diabetes stuck in neutral. Nearly half of the patients who can’t get their diabetes under control are carrying this hidden weight, and Sparrow Pharmaceuticals is betting their science can finally shut it down.
Their weapon is clofutriben, a once-daily oral inhibitor of 11β-hydroxysteroid dehydrogenase type 1, or HSD-1 for those without a PhD in biochemistry. Strip away the jargon and it means this: instead of spraying the fire hose on symptoms, clofutriben cuts intracellular cortisol where it lives. No adrenal crashes, no blunt hammer. A first-in-class precision move designed to turn treatment resistance into treatment response. If it works, the diabetes playbook doesn’t just get updated, it gets torched.
Sparrow Pharmaceuticals didn’t emerge out of nowhere. Back in 2013, Dr. David Katz saw value in a mechanism big pharma had shelved and spun it into a company. Fast forward, and the team is stacked. Robert Jacks, President and Chief Executive Officer, has steered biotechs through storms most founders never survive. Dr. Frank Czerwiec, Chief Medical Officer, brings decades in metabolic research. Add Dora Ferrari driving clinical ops, Jamie MacPherson keeping regulatory airtight, and Andre Richer orchestrating programs, the kind of crew that makes investors lean in, not lean back.
And the investors here aren’t dabbling. RA Capital Management and Forbion led the round, with OrbiMed, RiverVest Venture Partners, and U.S. Venture Partners following through. RA Capital Management’s Zach Scheiner and Forbion’s Nanna Lüneborg now sit on the board alongside OrbiMed’s Klaus Veitinger. That lineup tells you this isn’t a speculative ticket, it’s conviction capital.
So where does the $95 million go? Straight into proving clofutriben in the CAPTAIN-T2D Phase 2b trial, with a topline readout expected in 2027. Alongside, Sparrow Pharmaceuticals is expanding into polymyalgia rheumatica and autonomous cortisol secretion with clinical collaborations at Oxford and Sheffield. Outsourced GMP manufacturing, CRO-driven operations, global partnerships in the works, this is biotech sharpened like a scalpel, not built like a bureaucracy.
The upside is massive. If clofutriben clears its hurdles, the win won’t stop at blood sugar. We’re talking weight, blood pressure, lipids, bone health, and quality of life for millions underserved by current therapies. That’s a multi-billion-dollar shift, hiding in plain sight, waiting for someone bold enough to drag cortisol into the spotlight. Sparrow Pharmaceuticals just raised the money to take that swing.
